SAP、CRP对选凝素功能的抑制
|
摘要
血清淀粉样P蛋白(SAP)、C-反应蛋白(CRP)隶属于正五聚体蛋白家族(pentraxins)。SAP与CRP为肝脏表达的血清蛋白,它们在急性炎症反应中会急剧上调表达。在临床检测中,可以通过检测其表达水平来反映患者炎症水平,但是其在炎症中的确切功能却是未知的。选凝素家族蛋白(CD62)包括P-选凝素(P-selectin)、E-选凝素(E-selectin)和L-选凝素(L-selectin)等三种蛋白,它们是种单次跨膜糖蛋白。它们是炎症或者机体免疫过程中白细胞迁移的关键性粘附分子,但是目前人们并不知道究竟是什么在负调控选凝素的功能。
我们发现SAP、CRP可以与选凝素家族蛋白相互作用,同时发现它们可以抑制选凝素结合到HL-60(人多形核细胞株)上,而且鼠SAP还可以抑制白细胞在鼠微静脉上的滚动。更重要的是,在几种小鼠的炎症模型中,比如说:急性腹膜炎、急性胸膜炎、急性肺炎以及卵清蛋白(OVA)诱导的哮喘等模型中,SAP和CRP可以抑制白细胞(包括;中性粒细胞、嗜酸性粒细胞等)向炎症部位的迁移。而且在SAP转基因小鼠中,白细胞的迁移也会减弱,但是在SAP基因敲除小鼠中白细胞的迁移却是增强的。
我们的发现证明,炎症反应蛋白(SAP、CRP)是选凝素家族蛋白的内在性负反馈调控因子,它们可以调节炎症过程中白细胞向炎症部位迁移的规模。
Serum amyloid P component (SAP) and C-reactive protein (CRP) are two classic short pentraxins secreted by hepatocytes in response to inflammatory challenges. Although widely used as a clinical indicator for inflammation, the functional role of circulating acute-phase proteins remains poorly understood in acute inflammation. The selectin (CD62) family of cell adhesion molecules mediates leukocyte trafficking and plays essential roles in leukocyte recruitment in host defense and innate immunity. However, the feedback mechanism for negative regulation of selectin-mediated leukocyte adhesion is currently not well understood.
Here we report that SAP and CRP bound to P-, E- and L-selectins (CD62P, E and L), inhibiting selectin binding to human promyeloid HL-60 cells and neutralizing leukocyte rolling on activated capillary venules. Importantly, SAP and CRP potently suppressed infiltration and deposition of leukocytes, such as neutrophils and eosinophils, in several murine inflammatory models including allergic lung inflammation induced by ovalbumin (OVA) sensitization. Consistent with this result, leukocyte accumulation was significantly reduced in SAP transgenic mice, but dramatically exaggerated in SAP-deficient (SAP-/-) mice.
Our findings thus demonstrate that acute-phase proteins, such as SAP and CRP, act as endogenous inhibitors of all three selectins for negative modulation of leukocyte trafficking during inflammation.
我们发现SAP、CRP可以与选凝素家族蛋白相互作用,同时发现它们可以抑制选凝素结合到HL-60(人多形核细胞株)上,而且鼠SAP还可以抑制白细胞在鼠微静脉上的滚动。更重要的是,在几种小鼠的炎症模型中,比如说:急性腹膜炎、急性胸膜炎、急性肺炎以及卵清蛋白(OVA)诱导的哮喘等模型中,SAP和CRP可以抑制白细胞(包括;中性粒细胞、嗜酸性粒细胞等)向炎症部位的迁移。而且在SAP转基因小鼠中,白细胞的迁移也会减弱,但是在SAP基因敲除小鼠中白细胞的迁移却是增强的。
我们的发现证明,炎症反应蛋白(SAP、CRP)是选凝素家族蛋白的内在性负反馈调控因子,它们可以调节炎症过程中白细胞向炎症部位迁移的规模。
Serum amyloid P component (SAP) and C-reactive protein (CRP) are two classic short pentraxins secreted by hepatocytes in response to inflammatory challenges. Although widely used as a clinical indicator for inflammation, the functional role of circulating acute-phase proteins remains poorly understood in acute inflammation. The selectin (CD62) family of cell adhesion molecules mediates leukocyte trafficking and plays essential roles in leukocyte recruitment in host defense and innate immunity. However, the feedback mechanism for negative regulation of selectin-mediated leukocyte adhesion is currently not well understood.
Here we report that SAP and CRP bound to P-, E- and L-selectins (CD62P, E and L), inhibiting selectin binding to human promyeloid HL-60 cells and neutralizing leukocyte rolling on activated capillary venules. Importantly, SAP and CRP potently suppressed infiltration and deposition of leukocytes, such as neutrophils and eosinophils, in several murine inflammatory models including allergic lung inflammation induced by ovalbumin (OVA) sensitization. Consistent with this result, leukocyte accumulation was significantly reduced in SAP transgenic mice, but dramatically exaggerated in SAP-deficient (SAP-/-) mice.
Our findings thus demonstrate that acute-phase proteins, such as SAP and CRP, act as endogenous inhibitors of all three selectins for negative modulation of leukocyte trafficking during inflammation.
引文
1. McEver, R. P. 2002. P-selectin and PSGL-1: exploiting connections between inflammation and venous thrombosis. Thromb Haemost. 87, 364-365.
2. Furie, B., and Furie, B. C. 1995. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Thromb. Haemost. 74, 224-227.
3. Hartwell, D. W., and Wagner, D. D. 1999. New discoveries with mice mutant in endothelial and platelet selectins. Thromb. Haemost. 82, 850-857.
4. Laudanna, C, Kim, J. Y., Constantin, G., and Butcher E. 2002. Rapid leukocyte integrin activation by chemokines. Immunol Rev. 186, 37-46.
5. Geng, J.-G., Chen, M., and Chou, K.-C. 2004. P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis. Curr. Med. Chem. 11, 2153-2160.
6. Johnston, G. I., Cook, R. G., and McEver, R. P. 1989. Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. Cell 56, 1033-1044.
7. Anostario M Jr, Huang KS. 1995. Modulation of E-selectin structure/function by metal ions. Studies on limited proteolysis and metal ion regeneration. J. Biol. Chem. 270, 8138-8144.
8. Kansas GS. 1992. Structure and function of L-selectin. 100, 287-293.
9. Larsen, E., Celi. A., Gilbert, G. E., Furie, B. C., Erban, J. K., Bonfanti, R., Wagner, D. D., and Furie, B. 1989. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 59, 305-312.
10. Geng, J.-G., Bevilacqua, M. P., Moore, K. L., McIntyre, T. M., Prescott, S. M., Kim, J. M., Bliss, G. A., Zimmerman, G. A., and McEver, R. P. 1990. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature 343, 757-760.
11. Moore, K. L., Stults, N. L., Diaz, S., Smith, D. F., Cummings, R. D., Varki, A., and McEver, R. P. 1992. Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. J. Cell Biol. 118, 445-456.
12. Sako, D., Chang, X. J., Barone, K. M., Vachino, G., White, H. M., Shaw, G., Veldman, G. M., Bean, K. M., Ahern, T. J., Furie, B., Cumming, D. A., and Larsen, G. R. 1993. Expression cloning of a functional glycoprotein ligand for P-selectin. Cell 75, 1179-1186.
13. Ma, L., Raycroft, L., Asa, D., Anderson, D. C., and Geng, J.-G. 1994. A sialoglycoprotein from human leukocytes functions as a ligand for P-selectin. J. Biol. Chem. 269, 27739-27746.
14. Somers, W. S., Tang, J., Shaw, G. D., and Camphausen, R. T. 2001. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1. Cell 103, 467-479.
15. Mayadas, T. N., Johnson, R. C., Rayburn, H., Hynes, R. O., and Wagner, D. D. 1993. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 74, 541-54.
16. Subramaniam, M., Frenette, P. S., Saffaripour, S., Johnson, R. C., Hynes, R. O., and Wagner, D. D. 1996. Defects in hemostasis in P-selectin-deficient mice. Blood 87, 1238-1242.
17. Yang, J., Hirata, T., Croce, K., Merrill-Skoloff, G., Tchernychev, B., Williams, E., Flaumenhaft, R., Furie, B. C., and Furie, B. 1999. Targeted gene disruption demonstrates thatP-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration. J. Exp. Med. 190, 1769-82.
18. Wang H.B., Wang J.T., Zhang L., Geng Z.H., Xu W.L., Xu T., Huo Y., Zhu X., Plow E.F., Chen M. and Geng J.G. 2007. P-selectin primes leukocyte integrin activation during inflammation. Nat Immunol. 8, 882-892.
19. Debra J. Mitchell, Pauline Li, Paul H. Reinhardt and Paul Kubes, 2000. Importance of L-selectin–dependent leukocyte–leukocyte interactions in human whole blood. Blood. 95. 2954-2959.
20. Einar E. Eriksson, Xun Xie, Joachim Werr, Peter Thoren and Lennart Lindbom. 2001. Importance of Primary Capture and L-Selectin–dependent Secondary Capture in Leukocyte Accumulation in Inflammation and Atherosclerosis In Vivo. J. Exp. Med. 194, 205–217.
21. Palabrica, T., Lobb, R., Furie, B. C., Palabrica, T., Lobb, R., Furie, B. C., Aronovitz, M., Benjamin, C., Hsu, Y. M., Sajer, S. A., and Furie, B. 1992. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 359, 848-851.
22. Celi, A., Pellegrini, G., Lorenzet, R., Celi, A., Pellegrini, G., Lorenzet, R., De Blasi, A., Ready, N., Furie, B. C., and Furie, B. 1994. P-selectin induces the expression of tissue factor on monocytes. Proc. Natl. Acad. Sci. USA 91, 8767-8771.
23. Falati, S., Liu, Q., Gross, P., Merrill-Skoloff, G., Chou, J., Vandendries, E., Celi, A., Croce, K., Furie, B. C., and Furie, B. 2003. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J. Exp. Med. 197, 1585-1598.
24. Hrachovinova, I., Cambien, B., Hafezi-Moghadam, A., Kappelmayer, J., Camphausen, R. T., Widom, A., Xia, L., Kazazian, H. H. Jr., Schaub, R. G., McEver, R. P., and Wagner, D. D. 2003. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat. Med. 8, 1020-1025.
25. Toombs, C. F., DeGraaf, G. L., Martin, J. P., Geng, J.-G., Anderson, D. C., and Shebuski, R. J. 1995. Inhibition of P-selectin with the GA6 monoclonal antibody accelerates pharmacological thrombolysis in a primate model of arterial thrombosis. J. Pharmacol. Exp. Ther. 275, 941-49.
26. Wakefield, T. W., Strieter, R. M., Downing, L. J., Kadell, A. M., Wilke, C. A., Burdick, M. D., Wrobleski, S. K., Phillips, M. L., Paulson, J. C., Anderson, D. C., and Greenfield, L. J. 1996. P-selectin and TNF inhibition reduce venous thrombosis inflammation. J. Surg. Res. 64, 26-31.
27. Downing, L. J., Wakefield, T. W., Strieter, R. M., Prince, M. R., Londy, F. J., Fowlkes, J. B., Hulin, M. S., Kadell, A. M., Wilke, C. A., Brown, S. L., Wrobleski, S. K., Burdick, M. D., Anderson, D. C., and Greenfield, L. J. 1997. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J. Vasc. Surg. 25, 816-827.
28. Myers, D. D. Jr., Schaub, R., Wrobleski, S. K., Londy, F. J. 3rd., Fex, B. A., Chapman, A. M., Greenfield, L. J., and Wakefield, T. W. 2001. P-selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb. Haemost. 85, 423-429.
29. Myers, D. D. Jr., Henke, P. K., Wrobleski, S. K., Hawley, A. E., Farris, D. M., Chapman, A. M., Knipp, B. S., Thanaporn, P., Schaub, R. G., Greenfield, L. J., and Wakefield, T. W. 2002. P-selectin inhibition enhances thrombus resolution and decreases vein wall fibrosis in a rat model. J. Vasc. Surg. 36, 928-938.
30. Myers, D. Jr., Farris, D., Hawley, A., Wrobleski, S., Chapman, A., Stoolman, L., Knibbs, R., Strieter, R., and Wakefield, T. 2002. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. J. Surg. Res. 108, 212-221.
31. Sullivan, V. V., Hawley, A. E., Farris, D. M., Knipp, B. S., Varga, A. J., Wrobleski, S. K., Thanapron, P., Eagleton, M. J., Myers, D. D., Fowlkes, J. B., and Wakefield, T. W. 2003. Decrease in fibrin content of venous thrombi in selectin-deficient mice. J. Surg. Res. 109, 1-7.
32. Thanaporn, P., Myers, D. D., Wrobleski, S. K., Hawley, A. E., Farris, D. M., Wakefield, T. W., and Henke, P. K. 2003. P-selectin inhibition decreases post-thrombotic vein wall fibrosis in a rat model. Surgery 134, 365-371.
33. Myers, D. D., Hawley, A. E., Farris, D. M., Wrobleski, S. K., Thanaporn, P., Schaub, R. G., Wagner, D. D., Kumar, A., and Wakefield, T. W. 2003. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J. Vasc. Surg. 38, 1075-1089.
34. Frenette, P. S., Johnson, R. C., Hynes, R. O., and Wagner, D. D. 1995. Platelets roll on stimulated endothelium in vivo: An interaction mediated by endothelial P-selectin. Proc. Natl. Acad. Sci. USA 92, 7450-7454.
35. Frenette, P. S., Moyna, C., Hartwell, D.W., Lowe, J. B., Hynes, R. O., and Wagner, D. D. 1998. Platelet-endothelial interactions in inflamed mesenteric venules. Blood 91, 1318-1324.
36. Romo, G. M., Dong, J. F., Schade, A. J., Gardiner, E. E., Kansas, G. S., Li, C. Q., McIntire, L. V., Berndt, M. C., Lopez, J. A. 1999. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J. Exp. Med. 190, 803-814.
37. Frenette, P. S., Denis, C. V., Weiss, L., Jurk, K., Subbarao, S., Kehrel, B., Hartwig, J. H., Vestweber, D., and Wagner, D. D. 2000. P-selectin glycoprotein ligand 1 (PSGE-1) is expressed on platelets and can mediate platelet endothelial interactions in vivo. J. Exp. Med. 291, 1413-1422.
38. Li, L., Qian, K.-X., and Geng, J.-G. 2002. A 28-kDa glycoprotein functions as a platelet ligand for P-selectin (CD62P). Thromb. Haemost. 87, 706-711.
39. Menten, M.; and Thiagarajan P. 2000. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 102, 1931-1936.
40. Merten, M., Chow, T., Hellums, J. D., and Thiagarajan, P. 2000. A new role for P-selectin in shear-induced platelet aggregation. Circulation 102, 2045-2050.
41. Merten, M., and Thiagarajan, P. 2001. Role for sulfatides in platelet aggregation. Circulation 104, 2955-2960.
42. Kim, Y. J., Borsig, L., Varki, N. M., and Varki, A. 1998. P-selectin deficiency attenuates tumor growth and metastasis. Proc. Natl. Acad. Sci. USA. 95, 9325-9330.
43. Kaytes, P. K., and Geng, J.-G. 1998. P-selectin mediates adhesion of the human melanoma cell line NKI-4: Identification of glycoprotein ligands. Biochemistry 37, 10514-10521.
44. Li, L., Short, H. J., Qian, K.-X., Elhammer, ?. P., and Geng, J.-G. 2001. Characterization of glycoprotein ligands for P-selectin on a human small cell lung cancer cell line NCI-H345. Biochem. Biophys. Res. Comm. 288, 637-644.
45. Ma, Y.-Q., and Geng, J.-G. 2002. Obligatory requirement of sulfation for P-selectin binding to human salivary gland carcinoma Acc-M cells and breast carcinoma ZR-75-30 cells. J. Immunol. 168, 1690-1696.
46. Caine GJ, Lip GY, Stonelake PS, Ryan P and Blann AD. 2004. Platelet activation,coagulation and angiogenesis in breast and prostate carcinoma. Thromb. Haemost. 92, 185-190.
47. Caine GJ, Lip GY, Blann AD. 2004. Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Ann Med. 36, 273-277.
48. Caine GJ, Nadar SK, Lip GY, Stonelake PS, Blann AD. 2004. Platelet adhesion in breast cancer: development and application of a novel assay. Blood Coagul. Fibrinolysis. 15, 513-518.
49. Disdier, M., Morrissey, J. H., Fugate, R. D., Bainton, D. F., and McEver, R. P. 1992. Cytoplasmic domain of P-selectin (CD62) contains the signal for sorting into the regulated secretory pathway. Mol. Biol. Cell 3, 309-321.
50. Koedam, J. A., Cramer, E. M., Briend, E., Furie, B., Furie, B. C., and Wagner, D. D. 1992. P-selectin, a granule membrane protein of platelets and endothelial cells, follows the regulated secretory pathway in AtT-20 cells. J. Cell Biol. 116, 617-625.
51. Modderman, P. W., Beuling, E. A., Govers, L. A., Calafat, J., Janssen, H., Von dem Borne, A. E., and Sonnenberg, A. 1998. Determinants in the cytoplasmic domain of P-selectin required for sorting to secretory granules. Biochem. J. 336, 153-161.
52. Green, S. A., Setiadi, H., McEver, R. P., and Kelly, R. B. 1994. The cytoplasmic domain of P-selectin contains a sorting determinant that mediates rapid degradation in lysosomes. J. Cell Biol. 124, 435-448.
53. Norcott, J. P., Solari, R., and Cutler, D. F. 1996. Targeting of P-selectin to two regulated secretory organelles in PC12 cells. J. Cell Biol. 134, 1229-1240.
54. Blagoveshchenskaya, A. D., Norcott, J. P., and Cutler, D. F. 1998. Lysosomal targeting of P-selectin is mediated by a novel sequence within its cytoplasmic tail. J. Biol. Chem. 273, 2729-2737.
55. Blagoveshchenskaya, A. D., Hewitt, E. W., and Cutler, D. F. 1998. A balance of opposing signals within the cytoplasmic tail controls the lysosomal targeting of P-selectin. J. Biol. Chem. 273, 27896-27903.
56. Fleming, J. C., Berger, G., Guichard, J., Cramer, E. M., and Wagner, D. D. 1998. The transmembrane domain enhances granular targeting of P-selectin. Eur. J. Cell Biol. 75, 331-343.
57. Subramaniam, M., Koedam, J. A., and Wagner, D. D. 1993. Divergent fates of P- and E-selectins after their expression on the plasma membrane. Mol. Biol. Cell 8, 791-801.
58. Hartwell, D. W., Mayadas, T. N., Berger, G., Frenette, P. S., Rayburn, H., Hynes, R. O., and Wagner, D. D. 1998. Role of P-selectin cytoplasmic domain in granular targeting in vivo and in early inflammatory responses. J. Cell Biol. 143, 1129-1141.
59. Setiadi, H., Sedgewick, G., Erlandsen, S. L., and McEver, R. P. 1998. Interactions of the cytoplasmic domain of P-selectin with clathrin-coated pits enhance leukocyte adhesion under flow. J. Cell Biol. 142, 859-871.
60. Setiadi, H., and McEver, R. P. 2003. Signal-dependent distribution of cell surface P-selectin in clathrin-coated pits affects leukocyte rolling under flow. J. Cell Biol. 163, 1385-1395.
61. Blagoveshchenskaya, A. D., Hannah, M. J., Allen, S., and Cutler, D. F. 2002. Selective and signal-dependent recruitment of membrane proteins to secretory granules formed by heterologously expressed von Willebrand factor. Mol. Biol. Cell 13, 1582-1593.
62. Padilla, A., Moake, J. L., Bernardo, A., Ball, C., Wang, Y., Arya, M., Nolasco, L., Turner, N., Berndt, M. C., Anvari, B., Lopez, J. A., and Dong, J. F. 2004. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 103, 2150-2156.
63. Denis, C. V., Andre, P., Saffaripour, S., and Wagner, D. D. 2001. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proc. Natl. Acad. Sci. USA 98, 4072-4077.
64. Linda, M. Bradley., Susan R. Watson, Susan L. Swain. 1994. Entry of na?ve CD4 T Cells into peripheral lymph nodes requires L-selectin. J. Exp. Med. 180, 2401-2406.
65. Jianchao, Xu, Iqual, S. Grewal, Gregory, P. Geba and Richard A. Flavell. 1996. Impaired Primary T cell responses in L-selectin-deficient mice. J. Exp. Med. 183, 589-598.
66. Qizhi, Tang, Jeffrey A. 2006. Bluestone. Regulatory T-cell physiology and application to treat autoimmunity. Immunological Reviews. 212, 217–237.
67. Kristin V. Tarbell, Lucine Petit, Xiaopan Zuo, Priscilla Toy, Xunrong Luo, Amina Mqadmi, Hua Yang, Manikkam Suthanthiran, Svetlana Mojsov, and Ralph M. Steinman. 2007. Dendritic cell–expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204, 191–201.
68. Cunnane, G. 2001. Amyloid proteins in pathogenesis of AA amyloidosis. Lancet 358, 4-5.
69. Cunnane, G. 2001. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr. Opin. Rheumatol. 13, 67-73.
70. Coria, F., Castano, E., Prelli, F., Larrondo-Lillo, M., van Duinen, S., Shelanski, M. L., and Frangione, B. 1988. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab. Invest. 58, 454-458.
71. Steven Black, Irving Kushner and David Samols. 2004. C-reactive Protein. J. Biol. Chem.26, 48487-48491.
72. Pepys, M. B., Rademacher, T. W., Amatayakul-Chantler, S., Williams, P., Noble, G. E., Hutchinson, W. L., Hawkins, P. N., Nelson, S. R., Gallimore, J. R., Herbert, J., Hutton, T., and Dwek, R. A. 1994. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc. Natl. Acad. Sci. USA. 91, 5602-5606.
73. Emsley J., White H.E., O'Hara B.P., Oliva G., Srinivasan N., Tickle I.J., Blundell T.L., Pepys M.B. and Wood S.P. 1994. Structure of pentameric human serum amyloid P component Nature. 367, 338-345.
74. Shrive A.K., Cheetham G.M., Holden D., Myles D.A., Turnell W.G., Volanakis J.E., Pepys M.B., Bloomer A.C. and Greenhough T.J. 1996. Three dimensional structure of human C-reactive protein. Nat Struct Biol. 3, 346-354.
75. Cecilia Garlanda, Barbara Bottazzi, Antonio Bastone and Alberto Mantovani1. 2005. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu. Rev. Immunol. 23, 337–366.
76. Ghosh, S., May, M. J., and Kopp, E. B. 1998. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225-260.
77. Pepys, M.B., Baltz, M., Gomer, K., Davies, A.J.S. and Doenhoff, M. 1979. Serum amyloid P-component is an acute-phase reactant in the mouse. Nature 278, 259-261.
78. Hind C.R., Collins P.M., Renn D., Cook R.B., Caspi D., et al. 1984. Binding specificity ofserum amyloid P component for the pyruvate acetal of galactose. J. Exp. Med. 159, 1058–1069.
79. Noursadeghi M., Bickerstaff M.C., Gallimore J.R., Herbert J., Cohen J., Pepys M.B. 2000. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc. Natl. Acad. Sci. USA 97, 14584–14589.
80. Hind C.R., Collins P.M., Baltz M.L., Pepys M.B. 1985. Human serum amyloid P component, a circulating lectin with specificity for the cyclic 4,6-pyruvate acetal of galactose. Interactions with various bacteria. Biochem. J. 225,107–111.
81. Andersen O., Vilsgaard Ravn K., Juul Sorensen I., Jonson G., Holm Nielsen E., Svehag SE. 1997. Serum amyloid P component binds to influenzaAvirus haemagglutinin and inhibits the virus infection in vitro. Scand. J. Immunol. 46, 331–337
82. de Haas C.J., van der Tol M.E., Van Kessel K.P., Verhoef J., Van Strijp J.A.. 1998. A synthetic lipopolysaccharide-binding peptide based on amino acids 27–39 of serum amyloid P component inhibits lipopolysaccharide-induced responses in human blood. J. Immunol. 161, 3607–3615.
83. Loveless R.W., Floyd-O’Sullivan G., Raynes J.G., Yuen C.T., Feizi T. 1992. Human serum amyloid P is a multispecific adhesive protein whose ligands include 6-phosphorylated mannose and the 3-sulphated saccharides galactose, N-acetylgalactosamine and glucuronic acid. EMBO J. 11, 813–819.
84. Pepys M.B., Butler P.J. 1987. Serum amyloid P component is the major calciumdependent specific DNA binding protein of the serum. Biochem. Biophys. Res. Commun. 148, 308–313.
85. Butler P.J., Tennent G.A., Pepys M.B. 1990. Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin. J. Exp. Med. 172, 13–18.
86. Hohenester, E., Hutchinson, W. L., Pepys, M. B., and Wood, S. P. 1997. Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP. J. Mol. Biol. 269, 570-578.
87. Thompson1 D., Pepys M.B., Tickle and Wood S. 2002. the structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactose. J. Mol. Biol. 320, 1081–1086.
88. Pepys M.B., Herbert J., Hutchinson W.L., Tennent G.A., Lachmann H.J., Gallimore J.R., Lovat L.B., Bartfai T., Alanine A., Hertel C., Hoffmann T., Jakob-Roetne R., Norcross R.D., Kemp J.A., Yamamura K., Suzuki M., Taylor G.W., Murray S., Thompson D., Purvis A., Kolstoe S., Wood S.P., Hawkins P.N. 2002.Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 417, 254-259.
89. Szalai A.J. 2002. The antimicrobial activity of C-reactive protein. Microbes Infect. 4, 201–205.
90. Pepys M.B., Hirschfield G.M. 2003. Creactive protein: a critical update. J. Clin. Invest. 111, 1805–1812.
91. Gideon M. Hirschfield, 2004. Amyloidosis: a clinico-pathophysiological synopsis. Seminars in Cell & Developmental Biology. 15, 39–44.?
92. Pepys, M. B. 2001. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356, 203-210.
93. Bickerstaff, M. C., Botto, M., Hutchinson, W. L., Herbert, J., Tennent, G. A., Bybee, A.,Mitchell, D. A., Cook, H. T., Butler, P. J., Walport, M. J., and Pepys, M. B. 1999. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat. Med. 5, 694-7.
94. Shan-Ching Ying, Anita T.,Gewurz, Haixiang Jiang and Henry Gewurz. 1993. human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of Clq. J. Immuno. 150, 169-176.
95. Szalai A.J., Briles D.E., Volanakis J.E. 1995. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J. Immunol. 155, 2557–2563.
96. Weiser J.N., Pan N., Mc Gowan K.L., Musher D., Martin A., Richards J. 1998. Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J. Exp. Med. 187, 631–640.
97. Lysenko E., Richards J.C., Cox A.D., Stewart A., Martin A. et al. 2000. The position of phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae affects binding and sensitivity to C-reactive protein-mediated killing. Mol. Microbiol. 35:234–245.
98. Szalai A.J., VanCott J.L., McGhee J.R., Volanakis J.E., Benjamin W.H. Jr. 2000. Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect. Immun. 68, 5652–5656.
99. Szalai A.J., Nataf S., Hu X.Z., Barnum S.R. 2002. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J. Immunol. 168, 5792–5797.
100. Du Clos T.W., Zlock L.T., Hicks P.S., Mold C. 1994. Decreased autoantibody levels and enhanced survival of (NZB×NZW) F1 mice treated with C-reactive protein. Clin. Immunol. Immunopathol. 70, 22–27.
101. Xia D., Samols D. 1997. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc. Natl. Acad. Sci. USA. 94, 2575–2580.
102. Boxio, R., Bossenmeyer-Pourié, C., Steinckwich, N., Dournon, C. & N??e, O. 2004. Mouse bone marrow contains large numbers of functionally competent neutrophils. J. Leukoc. Biol. 75, 604-611.
103. Pepys, M. B. 1979. Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology 37, 637-641.
104. L.A. Trouw, M.A. Seelen,J.M.G.J. Duijs, H. Benediktsson, C. Van Kooten& M.R. Daha. 2003. Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin Exp Immunol. 132, :32–39.
105. McCafferty, D.-M., Kanwar, S., Granger D. N. & Kubes, P. 2000. E/P-selectin-deficient mice: an optimal mutation for abrogating antigen but not tumor necrosis factor-α-induced immune responses. Eur. J. Immunol. 30, 2362-2371.
106. Miotla, J. M., Ridger, V. C. & Hellewell, P. G. Dominant role of L- and P-selectin in mediating CXC chemokine-induced neutrophil migration in vivo. Brit. J. Pharmacol. 133, 550-556 (2001).
107. Stibenz, D. et al. Binding of human serum amyloid P component to L-selectin. Eur. J. Immunol. 36, 446-456 (2006).
108. Srensen, I.J., Nielsen, E.H., Andersen, O., Danielsen, B. & Svehag SE. 1996. Binding of complement proteins C1q and C4bp to serum amyloid P component (SAP) in solid contra liquid phase. Scand. J. Immunol. 44, 401-407.
109. Sen, J.W. & Heegaard, N.H.H. 2002. Serum amyloid P component does not circulate in complex C4-binding protein, fibronectin or any other major protein ligand. Scand. J. Immunol. 56, 85-93.
110. Hicks, P. S., Saunero-Nava, L., Du Clos, T. W., Mold, C. 1992. Serum amyloid P component binds to histones and activates the classical complement pathway. J. Immunol. 149, 3689-3694.
111. Schmidt, U., Wagner, H. & Miethke, T. 1999. CpG-DNA upregulates the major acute-phase proteins SAA and SAP. Cell. Microbiol. 1, 61-67.
112. Steeber, D. A., Green, N. E., Sato, S. & Tedder, T. F. 1996. Humoral immune responses in L-selectin-deficient mice. J. Immunol. 157, 4899-4907.
2. Furie, B., and Furie, B. C. 1995. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Thromb. Haemost. 74, 224-227.
3. Hartwell, D. W., and Wagner, D. D. 1999. New discoveries with mice mutant in endothelial and platelet selectins. Thromb. Haemost. 82, 850-857.
4. Laudanna, C, Kim, J. Y., Constantin, G., and Butcher E. 2002. Rapid leukocyte integrin activation by chemokines. Immunol Rev. 186, 37-46.
5. Geng, J.-G., Chen, M., and Chou, K.-C. 2004. P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis. Curr. Med. Chem. 11, 2153-2160.
6. Johnston, G. I., Cook, R. G., and McEver, R. P. 1989. Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. Cell 56, 1033-1044.
7. Anostario M Jr, Huang KS. 1995. Modulation of E-selectin structure/function by metal ions. Studies on limited proteolysis and metal ion regeneration. J. Biol. Chem. 270, 8138-8144.
8. Kansas GS. 1992. Structure and function of L-selectin. 100, 287-293.
9. Larsen, E., Celi. A., Gilbert, G. E., Furie, B. C., Erban, J. K., Bonfanti, R., Wagner, D. D., and Furie, B. 1989. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell 59, 305-312.
10. Geng, J.-G., Bevilacqua, M. P., Moore, K. L., McIntyre, T. M., Prescott, S. M., Kim, J. M., Bliss, G. A., Zimmerman, G. A., and McEver, R. P. 1990. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature 343, 757-760.
11. Moore, K. L., Stults, N. L., Diaz, S., Smith, D. F., Cummings, R. D., Varki, A., and McEver, R. P. 1992. Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. J. Cell Biol. 118, 445-456.
12. Sako, D., Chang, X. J., Barone, K. M., Vachino, G., White, H. M., Shaw, G., Veldman, G. M., Bean, K. M., Ahern, T. J., Furie, B., Cumming, D. A., and Larsen, G. R. 1993. Expression cloning of a functional glycoprotein ligand for P-selectin. Cell 75, 1179-1186.
13. Ma, L., Raycroft, L., Asa, D., Anderson, D. C., and Geng, J.-G. 1994. A sialoglycoprotein from human leukocytes functions as a ligand for P-selectin. J. Biol. Chem. 269, 27739-27746.
14. Somers, W. S., Tang, J., Shaw, G. D., and Camphausen, R. T. 2001. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1. Cell 103, 467-479.
15. Mayadas, T. N., Johnson, R. C., Rayburn, H., Hynes, R. O., and Wagner, D. D. 1993. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell 74, 541-54.
16. Subramaniam, M., Frenette, P. S., Saffaripour, S., Johnson, R. C., Hynes, R. O., and Wagner, D. D. 1996. Defects in hemostasis in P-selectin-deficient mice. Blood 87, 1238-1242.
17. Yang, J., Hirata, T., Croce, K., Merrill-Skoloff, G., Tchernychev, B., Williams, E., Flaumenhaft, R., Furie, B. C., and Furie, B. 1999. Targeted gene disruption demonstrates thatP-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration. J. Exp. Med. 190, 1769-82.
18. Wang H.B., Wang J.T., Zhang L., Geng Z.H., Xu W.L., Xu T., Huo Y., Zhu X., Plow E.F., Chen M. and Geng J.G. 2007. P-selectin primes leukocyte integrin activation during inflammation. Nat Immunol. 8, 882-892.
19. Debra J. Mitchell, Pauline Li, Paul H. Reinhardt and Paul Kubes, 2000. Importance of L-selectin–dependent leukocyte–leukocyte interactions in human whole blood. Blood. 95. 2954-2959.
20. Einar E. Eriksson, Xun Xie, Joachim Werr, Peter Thoren and Lennart Lindbom. 2001. Importance of Primary Capture and L-Selectin–dependent Secondary Capture in Leukocyte Accumulation in Inflammation and Atherosclerosis In Vivo. J. Exp. Med. 194, 205–217.
21. Palabrica, T., Lobb, R., Furie, B. C., Palabrica, T., Lobb, R., Furie, B. C., Aronovitz, M., Benjamin, C., Hsu, Y. M., Sajer, S. A., and Furie, B. 1992. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 359, 848-851.
22. Celi, A., Pellegrini, G., Lorenzet, R., Celi, A., Pellegrini, G., Lorenzet, R., De Blasi, A., Ready, N., Furie, B. C., and Furie, B. 1994. P-selectin induces the expression of tissue factor on monocytes. Proc. Natl. Acad. Sci. USA 91, 8767-8771.
23. Falati, S., Liu, Q., Gross, P., Merrill-Skoloff, G., Chou, J., Vandendries, E., Celi, A., Croce, K., Furie, B. C., and Furie, B. 2003. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J. Exp. Med. 197, 1585-1598.
24. Hrachovinova, I., Cambien, B., Hafezi-Moghadam, A., Kappelmayer, J., Camphausen, R. T., Widom, A., Xia, L., Kazazian, H. H. Jr., Schaub, R. G., McEver, R. P., and Wagner, D. D. 2003. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat. Med. 8, 1020-1025.
25. Toombs, C. F., DeGraaf, G. L., Martin, J. P., Geng, J.-G., Anderson, D. C., and Shebuski, R. J. 1995. Inhibition of P-selectin with the GA6 monoclonal antibody accelerates pharmacological thrombolysis in a primate model of arterial thrombosis. J. Pharmacol. Exp. Ther. 275, 941-49.
26. Wakefield, T. W., Strieter, R. M., Downing, L. J., Kadell, A. M., Wilke, C. A., Burdick, M. D., Wrobleski, S. K., Phillips, M. L., Paulson, J. C., Anderson, D. C., and Greenfield, L. J. 1996. P-selectin and TNF inhibition reduce venous thrombosis inflammation. J. Surg. Res. 64, 26-31.
27. Downing, L. J., Wakefield, T. W., Strieter, R. M., Prince, M. R., Londy, F. J., Fowlkes, J. B., Hulin, M. S., Kadell, A. M., Wilke, C. A., Brown, S. L., Wrobleski, S. K., Burdick, M. D., Anderson, D. C., and Greenfield, L. J. 1997. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis. J. Vasc. Surg. 25, 816-827.
28. Myers, D. D. Jr., Schaub, R., Wrobleski, S. K., Londy, F. J. 3rd., Fex, B. A., Chapman, A. M., Greenfield, L. J., and Wakefield, T. W. 2001. P-selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb. Haemost. 85, 423-429.
29. Myers, D. D. Jr., Henke, P. K., Wrobleski, S. K., Hawley, A. E., Farris, D. M., Chapman, A. M., Knipp, B. S., Thanaporn, P., Schaub, R. G., Greenfield, L. J., and Wakefield, T. W. 2002. P-selectin inhibition enhances thrombus resolution and decreases vein wall fibrosis in a rat model. J. Vasc. Surg. 36, 928-938.
30. Myers, D. Jr., Farris, D., Hawley, A., Wrobleski, S., Chapman, A., Stoolman, L., Knibbs, R., Strieter, R., and Wakefield, T. 2002. Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. J. Surg. Res. 108, 212-221.
31. Sullivan, V. V., Hawley, A. E., Farris, D. M., Knipp, B. S., Varga, A. J., Wrobleski, S. K., Thanapron, P., Eagleton, M. J., Myers, D. D., Fowlkes, J. B., and Wakefield, T. W. 2003. Decrease in fibrin content of venous thrombi in selectin-deficient mice. J. Surg. Res. 109, 1-7.
32. Thanaporn, P., Myers, D. D., Wrobleski, S. K., Hawley, A. E., Farris, D. M., Wakefield, T. W., and Henke, P. K. 2003. P-selectin inhibition decreases post-thrombotic vein wall fibrosis in a rat model. Surgery 134, 365-371.
33. Myers, D. D., Hawley, A. E., Farris, D. M., Wrobleski, S. K., Thanaporn, P., Schaub, R. G., Wagner, D. D., Kumar, A., and Wakefield, T. W. 2003. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J. Vasc. Surg. 38, 1075-1089.
34. Frenette, P. S., Johnson, R. C., Hynes, R. O., and Wagner, D. D. 1995. Platelets roll on stimulated endothelium in vivo: An interaction mediated by endothelial P-selectin. Proc. Natl. Acad. Sci. USA 92, 7450-7454.
35. Frenette, P. S., Moyna, C., Hartwell, D.W., Lowe, J. B., Hynes, R. O., and Wagner, D. D. 1998. Platelet-endothelial interactions in inflamed mesenteric venules. Blood 91, 1318-1324.
36. Romo, G. M., Dong, J. F., Schade, A. J., Gardiner, E. E., Kansas, G. S., Li, C. Q., McIntire, L. V., Berndt, M. C., Lopez, J. A. 1999. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J. Exp. Med. 190, 803-814.
37. Frenette, P. S., Denis, C. V., Weiss, L., Jurk, K., Subbarao, S., Kehrel, B., Hartwig, J. H., Vestweber, D., and Wagner, D. D. 2000. P-selectin glycoprotein ligand 1 (PSGE-1) is expressed on platelets and can mediate platelet endothelial interactions in vivo. J. Exp. Med. 291, 1413-1422.
38. Li, L., Qian, K.-X., and Geng, J.-G. 2002. A 28-kDa glycoprotein functions as a platelet ligand for P-selectin (CD62P). Thromb. Haemost. 87, 706-711.
39. Menten, M.; and Thiagarajan P. 2000. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation 102, 1931-1936.
40. Merten, M., Chow, T., Hellums, J. D., and Thiagarajan, P. 2000. A new role for P-selectin in shear-induced platelet aggregation. Circulation 102, 2045-2050.
41. Merten, M., and Thiagarajan, P. 2001. Role for sulfatides in platelet aggregation. Circulation 104, 2955-2960.
42. Kim, Y. J., Borsig, L., Varki, N. M., and Varki, A. 1998. P-selectin deficiency attenuates tumor growth and metastasis. Proc. Natl. Acad. Sci. USA. 95, 9325-9330.
43. Kaytes, P. K., and Geng, J.-G. 1998. P-selectin mediates adhesion of the human melanoma cell line NKI-4: Identification of glycoprotein ligands. Biochemistry 37, 10514-10521.
44. Li, L., Short, H. J., Qian, K.-X., Elhammer, ?. P., and Geng, J.-G. 2001. Characterization of glycoprotein ligands for P-selectin on a human small cell lung cancer cell line NCI-H345. Biochem. Biophys. Res. Comm. 288, 637-644.
45. Ma, Y.-Q., and Geng, J.-G. 2002. Obligatory requirement of sulfation for P-selectin binding to human salivary gland carcinoma Acc-M cells and breast carcinoma ZR-75-30 cells. J. Immunol. 168, 1690-1696.
46. Caine GJ, Lip GY, Stonelake PS, Ryan P and Blann AD. 2004. Platelet activation,coagulation and angiogenesis in breast and prostate carcinoma. Thromb. Haemost. 92, 185-190.
47. Caine GJ, Lip GY, Blann AD. 2004. Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Ann Med. 36, 273-277.
48. Caine GJ, Nadar SK, Lip GY, Stonelake PS, Blann AD. 2004. Platelet adhesion in breast cancer: development and application of a novel assay. Blood Coagul. Fibrinolysis. 15, 513-518.
49. Disdier, M., Morrissey, J. H., Fugate, R. D., Bainton, D. F., and McEver, R. P. 1992. Cytoplasmic domain of P-selectin (CD62) contains the signal for sorting into the regulated secretory pathway. Mol. Biol. Cell 3, 309-321.
50. Koedam, J. A., Cramer, E. M., Briend, E., Furie, B., Furie, B. C., and Wagner, D. D. 1992. P-selectin, a granule membrane protein of platelets and endothelial cells, follows the regulated secretory pathway in AtT-20 cells. J. Cell Biol. 116, 617-625.
51. Modderman, P. W., Beuling, E. A., Govers, L. A., Calafat, J., Janssen, H., Von dem Borne, A. E., and Sonnenberg, A. 1998. Determinants in the cytoplasmic domain of P-selectin required for sorting to secretory granules. Biochem. J. 336, 153-161.
52. Green, S. A., Setiadi, H., McEver, R. P., and Kelly, R. B. 1994. The cytoplasmic domain of P-selectin contains a sorting determinant that mediates rapid degradation in lysosomes. J. Cell Biol. 124, 435-448.
53. Norcott, J. P., Solari, R., and Cutler, D. F. 1996. Targeting of P-selectin to two regulated secretory organelles in PC12 cells. J. Cell Biol. 134, 1229-1240.
54. Blagoveshchenskaya, A. D., Norcott, J. P., and Cutler, D. F. 1998. Lysosomal targeting of P-selectin is mediated by a novel sequence within its cytoplasmic tail. J. Biol. Chem. 273, 2729-2737.
55. Blagoveshchenskaya, A. D., Hewitt, E. W., and Cutler, D. F. 1998. A balance of opposing signals within the cytoplasmic tail controls the lysosomal targeting of P-selectin. J. Biol. Chem. 273, 27896-27903.
56. Fleming, J. C., Berger, G., Guichard, J., Cramer, E. M., and Wagner, D. D. 1998. The transmembrane domain enhances granular targeting of P-selectin. Eur. J. Cell Biol. 75, 331-343.
57. Subramaniam, M., Koedam, J. A., and Wagner, D. D. 1993. Divergent fates of P- and E-selectins after their expression on the plasma membrane. Mol. Biol. Cell 8, 791-801.
58. Hartwell, D. W., Mayadas, T. N., Berger, G., Frenette, P. S., Rayburn, H., Hynes, R. O., and Wagner, D. D. 1998. Role of P-selectin cytoplasmic domain in granular targeting in vivo and in early inflammatory responses. J. Cell Biol. 143, 1129-1141.
59. Setiadi, H., Sedgewick, G., Erlandsen, S. L., and McEver, R. P. 1998. Interactions of the cytoplasmic domain of P-selectin with clathrin-coated pits enhance leukocyte adhesion under flow. J. Cell Biol. 142, 859-871.
60. Setiadi, H., and McEver, R. P. 2003. Signal-dependent distribution of cell surface P-selectin in clathrin-coated pits affects leukocyte rolling under flow. J. Cell Biol. 163, 1385-1395.
61. Blagoveshchenskaya, A. D., Hannah, M. J., Allen, S., and Cutler, D. F. 2002. Selective and signal-dependent recruitment of membrane proteins to secretory granules formed by heterologously expressed von Willebrand factor. Mol. Biol. Cell 13, 1582-1593.
62. Padilla, A., Moake, J. L., Bernardo, A., Ball, C., Wang, Y., Arya, M., Nolasco, L., Turner, N., Berndt, M. C., Anvari, B., Lopez, J. A., and Dong, J. F. 2004. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 103, 2150-2156.
63. Denis, C. V., Andre, P., Saffaripour, S., and Wagner, D. D. 2001. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proc. Natl. Acad. Sci. USA 98, 4072-4077.
64. Linda, M. Bradley., Susan R. Watson, Susan L. Swain. 1994. Entry of na?ve CD4 T Cells into peripheral lymph nodes requires L-selectin. J. Exp. Med. 180, 2401-2406.
65. Jianchao, Xu, Iqual, S. Grewal, Gregory, P. Geba and Richard A. Flavell. 1996. Impaired Primary T cell responses in L-selectin-deficient mice. J. Exp. Med. 183, 589-598.
66. Qizhi, Tang, Jeffrey A. 2006. Bluestone. Regulatory T-cell physiology and application to treat autoimmunity. Immunological Reviews. 212, 217–237.
67. Kristin V. Tarbell, Lucine Petit, Xiaopan Zuo, Priscilla Toy, Xunrong Luo, Amina Mqadmi, Hua Yang, Manikkam Suthanthiran, Svetlana Mojsov, and Ralph M. Steinman. 2007. Dendritic cell–expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204, 191–201.
68. Cunnane, G. 2001. Amyloid proteins in pathogenesis of AA amyloidosis. Lancet 358, 4-5.
69. Cunnane, G. 2001. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr. Opin. Rheumatol. 13, 67-73.
70. Coria, F., Castano, E., Prelli, F., Larrondo-Lillo, M., van Duinen, S., Shelanski, M. L., and Frangione, B. 1988. Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab. Invest. 58, 454-458.
71. Steven Black, Irving Kushner and David Samols. 2004. C-reactive Protein. J. Biol. Chem.26, 48487-48491.
72. Pepys, M. B., Rademacher, T. W., Amatayakul-Chantler, S., Williams, P., Noble, G. E., Hutchinson, W. L., Hawkins, P. N., Nelson, S. R., Gallimore, J. R., Herbert, J., Hutton, T., and Dwek, R. A. 1994. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc. Natl. Acad. Sci. USA. 91, 5602-5606.
73. Emsley J., White H.E., O'Hara B.P., Oliva G., Srinivasan N., Tickle I.J., Blundell T.L., Pepys M.B. and Wood S.P. 1994. Structure of pentameric human serum amyloid P component Nature. 367, 338-345.
74. Shrive A.K., Cheetham G.M., Holden D., Myles D.A., Turnell W.G., Volanakis J.E., Pepys M.B., Bloomer A.C. and Greenhough T.J. 1996. Three dimensional structure of human C-reactive protein. Nat Struct Biol. 3, 346-354.
75. Cecilia Garlanda, Barbara Bottazzi, Antonio Bastone and Alberto Mantovani1. 2005. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu. Rev. Immunol. 23, 337–366.
76. Ghosh, S., May, M. J., and Kopp, E. B. 1998. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225-260.
77. Pepys, M.B., Baltz, M., Gomer, K., Davies, A.J.S. and Doenhoff, M. 1979. Serum amyloid P-component is an acute-phase reactant in the mouse. Nature 278, 259-261.
78. Hind C.R., Collins P.M., Renn D., Cook R.B., Caspi D., et al. 1984. Binding specificity ofserum amyloid P component for the pyruvate acetal of galactose. J. Exp. Med. 159, 1058–1069.
79. Noursadeghi M., Bickerstaff M.C., Gallimore J.R., Herbert J., Cohen J., Pepys M.B. 2000. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc. Natl. Acad. Sci. USA 97, 14584–14589.
80. Hind C.R., Collins P.M., Baltz M.L., Pepys M.B. 1985. Human serum amyloid P component, a circulating lectin with specificity for the cyclic 4,6-pyruvate acetal of galactose. Interactions with various bacteria. Biochem. J. 225,107–111.
81. Andersen O., Vilsgaard Ravn K., Juul Sorensen I., Jonson G., Holm Nielsen E., Svehag SE. 1997. Serum amyloid P component binds to influenzaAvirus haemagglutinin and inhibits the virus infection in vitro. Scand. J. Immunol. 46, 331–337
82. de Haas C.J., van der Tol M.E., Van Kessel K.P., Verhoef J., Van Strijp J.A.. 1998. A synthetic lipopolysaccharide-binding peptide based on amino acids 27–39 of serum amyloid P component inhibits lipopolysaccharide-induced responses in human blood. J. Immunol. 161, 3607–3615.
83. Loveless R.W., Floyd-O’Sullivan G., Raynes J.G., Yuen C.T., Feizi T. 1992. Human serum amyloid P is a multispecific adhesive protein whose ligands include 6-phosphorylated mannose and the 3-sulphated saccharides galactose, N-acetylgalactosamine and glucuronic acid. EMBO J. 11, 813–819.
84. Pepys M.B., Butler P.J. 1987. Serum amyloid P component is the major calciumdependent specific DNA binding protein of the serum. Biochem. Biophys. Res. Commun. 148, 308–313.
85. Butler P.J., Tennent G.A., Pepys M.B. 1990. Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin. J. Exp. Med. 172, 13–18.
86. Hohenester, E., Hutchinson, W. L., Pepys, M. B., and Wood, S. P. 1997. Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP. J. Mol. Biol. 269, 570-578.
87. Thompson1 D., Pepys M.B., Tickle and Wood S. 2002. the structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactose. J. Mol. Biol. 320, 1081–1086.
88. Pepys M.B., Herbert J., Hutchinson W.L., Tennent G.A., Lachmann H.J., Gallimore J.R., Lovat L.B., Bartfai T., Alanine A., Hertel C., Hoffmann T., Jakob-Roetne R., Norcross R.D., Kemp J.A., Yamamura K., Suzuki M., Taylor G.W., Murray S., Thompson D., Purvis A., Kolstoe S., Wood S.P., Hawkins P.N. 2002.Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 417, 254-259.
89. Szalai A.J. 2002. The antimicrobial activity of C-reactive protein. Microbes Infect. 4, 201–205.
90. Pepys M.B., Hirschfield G.M. 2003. Creactive protein: a critical update. J. Clin. Invest. 111, 1805–1812.
91. Gideon M. Hirschfield, 2004. Amyloidosis: a clinico-pathophysiological synopsis. Seminars in Cell & Developmental Biology. 15, 39–44.?
92. Pepys, M. B. 2001. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356, 203-210.
93. Bickerstaff, M. C., Botto, M., Hutchinson, W. L., Herbert, J., Tennent, G. A., Bybee, A.,Mitchell, D. A., Cook, H. T., Butler, P. J., Walport, M. J., and Pepys, M. B. 1999. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat. Med. 5, 694-7.
94. Shan-Ching Ying, Anita T.,Gewurz, Haixiang Jiang and Henry Gewurz. 1993. human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of Clq. J. Immuno. 150, 169-176.
95. Szalai A.J., Briles D.E., Volanakis J.E. 1995. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J. Immunol. 155, 2557–2563.
96. Weiser J.N., Pan N., Mc Gowan K.L., Musher D., Martin A., Richards J. 1998. Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J. Exp. Med. 187, 631–640.
97. Lysenko E., Richards J.C., Cox A.D., Stewart A., Martin A. et al. 2000. The position of phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae affects binding and sensitivity to C-reactive protein-mediated killing. Mol. Microbiol. 35:234–245.
98. Szalai A.J., VanCott J.L., McGhee J.R., Volanakis J.E., Benjamin W.H. Jr. 2000. Human C-reactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice. Infect. Immun. 68, 5652–5656.
99. Szalai A.J., Nataf S., Hu X.Z., Barnum S.R. 2002. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J. Immunol. 168, 5792–5797.
100. Du Clos T.W., Zlock L.T., Hicks P.S., Mold C. 1994. Decreased autoantibody levels and enhanced survival of (NZB×NZW) F1 mice treated with C-reactive protein. Clin. Immunol. Immunopathol. 70, 22–27.
101. Xia D., Samols D. 1997. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia. Proc. Natl. Acad. Sci. USA. 94, 2575–2580.
102. Boxio, R., Bossenmeyer-Pourié, C., Steinckwich, N., Dournon, C. & N??e, O. 2004. Mouse bone marrow contains large numbers of functionally competent neutrophils. J. Leukoc. Biol. 75, 604-611.
103. Pepys, M. B. 1979. Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology 37, 637-641.
104. L.A. Trouw, M.A. Seelen,J.M.G.J. Duijs, H. Benediktsson, C. Van Kooten& M.R. Daha. 2003. Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin Exp Immunol. 132, :32–39.
105. McCafferty, D.-M., Kanwar, S., Granger D. N. & Kubes, P. 2000. E/P-selectin-deficient mice: an optimal mutation for abrogating antigen but not tumor necrosis factor-α-induced immune responses. Eur. J. Immunol. 30, 2362-2371.
106. Miotla, J. M., Ridger, V. C. & Hellewell, P. G. Dominant role of L- and P-selectin in mediating CXC chemokine-induced neutrophil migration in vivo. Brit. J. Pharmacol. 133, 550-556 (2001).
107. Stibenz, D. et al. Binding of human serum amyloid P component to L-selectin. Eur. J. Immunol. 36, 446-456 (2006).
108. Srensen, I.J., Nielsen, E.H., Andersen, O., Danielsen, B. & Svehag SE. 1996. Binding of complement proteins C1q and C4bp to serum amyloid P component (SAP) in solid contra liquid phase. Scand. J. Immunol. 44, 401-407.
109. Sen, J.W. & Heegaard, N.H.H. 2002. Serum amyloid P component does not circulate in complex C4-binding protein, fibronectin or any other major protein ligand. Scand. J. Immunol. 56, 85-93.
110. Hicks, P. S., Saunero-Nava, L., Du Clos, T. W., Mold, C. 1992. Serum amyloid P component binds to histones and activates the classical complement pathway. J. Immunol. 149, 3689-3694.
111. Schmidt, U., Wagner, H. & Miethke, T. 1999. CpG-DNA upregulates the major acute-phase proteins SAA and SAP. Cell. Microbiol. 1, 61-67.
112. Steeber, D. A., Green, N. E., Sato, S. & Tedder, T. F. 1996. Humoral immune responses in L-selectin-deficient mice. J. Immunol. 157, 4899-4907.